On August 28, 2024 PDX Pharma reported the company was granted a new EU patent (EP3270932) on August 21, 2024, covering the composition and method of use for our innovative Pdx-NP nanoparticle platform (Press release, PDX Pharmaceuticals, AUG 28, 2024, View Source [SID1234646305]). Developed as a polymer-coated mesoporous silica alternative to lipid-based particles, which tend to home to the liver, Pdx-NP is the core nanotechnology behind all of PDX Pharmaceuticals’ pipelines. These include the HER2-targeted therapy T-siHER2-NP, the radiation sensitizer PETTRA, the immunotherapeutics ARAC and AIRISE, the nano-cytokine CK-NP for cancer treatments, and the AIRISE-VAC vaccine platforms for infectious diseases. This patent strengthens our IP beyond the U.S. patent (US11207428) issued in December 2021, bolstering our commercialization efforts. Congratulations to the inventors from PDX Pharma and OHSU, including Drs. Wassana Yantasee, Worapol (Boom) Ngamcherdtrakul, Joe Gray, Jingga Morry, and David Castro.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!